CClinicalTrials.gg
CompletedNCT02524548Updated Jun 29, 2020

SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors

An interventional study of SMS reminder in Breast Cancer and Medication Adherence, sponsored by National University of Singapore. Completed at 2 sites in Singapore. Open to female participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-06-29.

Sponsored by National University of Singapore · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2015, registered Aug 2015).
Phase
Not applicable
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
Female
01

Study summary

The purpose of this study is to determine whether weekly SMS reminders are effective in improving medication adherence of adjuvant aromatase inhibitors in women with breast cancer.

Read the detailed description

This study is a prospective randomised controlled parallel trial of SMS reminder versus standard care to investigate whether SMS reminder improves adherence to oral aromatase inhibitor (AI) therapy amongst women with breast cancer at 1-year follow-up.

All subjects will be randomised to receive either SMS reminder or standard care in a 1:1 ratio. Balanced permuted block randomisation will be implemented with random varying of block sizes of 4 or 6.

The sample size is estimated based on the primary endpoint of medication adherence (as measured via SMAQ) at 1-year. Assuming that the proportion of medication adherence in the intervention and control groups are 80% and 60% respectively, then based on a 5% significance level and a power of 90%, a minimum sample of 240 subjects (i.e. 120 per group) will be required. Further assuming an attrition rate of 10%, the anticipated trial size is 280 overall.

The assessment of medication adherence at 1-year (as measured via SMAQ) between the SMS reminder and control groups will be made using chi-square test. Adjustment for baseline covariate and potential confounders will be made using the logistic regression where appropriate.

Other measures of adherence such as the 1-year MPR, PDC and pill count will be compared between treatment arms via the t- test, with adjustment for confounders made via the analysis of covariance (ANCOVA).

Natural log transformation will be implemented on the estrone and androstenedione measures to normalise the data. The assessment of secondary outcomes involving the log transformed estrone and androstenedione levels will be made using the analysis of covariance (ANCOVA) to adjust for the respective baseline levels and other potential confounders. Comparison of estradiol levels (defined as \<18.4 versus ≥18.4) between the two arms will be made using chi-square test. The logistic regression analysis will be implemented to adjust for baseline covariate and other potential confounders where appropriate.

The assessment of knowledge, attitude, behavior, as well as barrier and facilitating factors between the intervention and control groups will be made using chi-square test, with treatment effect quantified based on odds ratio estimate and its 95% CI. Further adjustment for baseline scores and other potential confounders will be made using the logistic regression where appropriate.

Additionally, the investigators will compare the 4 different measures of adherence in a separate paper, to determine which of these provide a more meaningful or reliable information in the local context based on sensitivity analysis.

All analyses will be performed according to intention-to-treat using STATA, assuming a two-sided test at the 5% level of significance.

02

Conditions studied

  • Breast Cancer
  • Medication Adherence

Browse trials for

Keywords

  • Aromatase inhibitors
  • Reminder Systems
03

In context

Breast Neoplasms

12,543 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's enrollment of 244 is above the median of 72 across 9,302 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

National University of Singapore is the lead sponsor of 206 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Women who have been receiving adjuvant endocrine therapy for at least 1 year, and are continuing to receive adjuvant AI therapy for at least 1 more year.
  2. Have cellular phone that can receive text messages.
  3. Singaporean or permanent resident who is currently residing in Singapore.
  4. Able to give informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Unable or not willing to comply with study procedures.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
244 participants (actual)

Study arms

  • Experimental
    SMS reminder

    Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor

    Other: SMS reminder

  • No intervention
    Standard care

    Routine care

Interventions

  • OtherSMS reminder

    Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor for 1 year

06

What researchers measure

Primary outcomes

  1. Medication adherence

    Simplified medication adherence questionnaire (SMAQ)

    Time frame: One year

Secondary outcomes

  1. Androstenedione

    in nmol/L

    Time frame: One year

  2. Estrone

    in pg/mL

    Time frame: One year

  3. Estradiol

    in pmol/L

    Time frame: One year

Other outcomes

  1. Patients' knowledge, attitude, and behavior towards medication adherence

    The Beliefs about Medicines Questionnaire (BMQ)

    Time frame: One year

  2. Patients' knowledge, attitude, and behavior towards medication adherence

    Adherence Starts with Knowledge (ASK)-12 survey

    Time frame: One year

07

Study locations

2 sites
  • National University Hospital
    Singapore, 119628, Singapore
  • Ng Teng Fong General Hospital
    Singapore, 609606, Singapore
08

References and documents

Publications

  • He Y, Tan EH, Wong ALA, Tan CC, Wong P, Lee SC, Tai BC. Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: study protocol of a randomised controlled trial to evaluate the effect of short message service (SMS) reminder. BMC Cancer. 2018 Jul 9;18(1):727. doi: 10.1186/s12885-018-4660-7. PubMed 29986672 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02524548
Lead sponsor
National University of Singapore
Collaborators
National University Cancer Institute, Singapore, Singapore Cancer Society
Responsible party
Bee-Choo Tai (Associate Professor, National University of Singapore) — Principal investigator
First posted
Aug 17, 2015
Start date
May 2015
Primary completion
Dec 2019
Completion
Jan 2020
Last update
Jun 29, 2020

Study contacts

Bee Choo Tai, PhD
principal investigator · National University of Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion